Semaglutide

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a pivotal therapeutic option for individuals managing type 2 diabetes in conjunction with diet and exercise to optimize glycemic control. Boasting a remarkable 94% sequence homology to human GLP-1, semaglutide serves as a potent mimic of this key regulatory peptide. By binding to the GLP-1 receptor, it triggers a cascade of physiological responses, including heightened insulin production and decreased glucagon secretion. Beyond its role as a GLP-1 receptor agonist, semaglutide exerts multifaceted effects, influencing the digestive tract by delaying gastrointestinal emptying, inducing satiety through appetite suppression in the brain, and contributing to vascular health by repairing damaged intima and enhancing endothelial function.